Consistent with previous research findings, Sun et al. reported that MenSC-Exo treatment improved BLM-induced pulmonary fibrosis by inhibiting ROS and NLRP3 inflammasome activation [36]. Here, NLRP3 is linked to pulmonary fibrosis.